Each of the participants at the Portofino Workshop was either an adopter or implementer of Systems Biology in industry, a developer of underpinning methods and/or technologies, an academic exploring its application to study disease, or even as a sponsor of research in this field. Each offered a particular perspective that is relevant to the key question of how to derive the greatest impact and to optimise return on investment for the benefit of human health. The output summarised in the Nature Commentary and in the forthcoming White Paper reflects the energetic and enthusiastic contributions by of all of the following, a number of whom were present as interested individuals rather than formal representatives of their organisations:

Alison Abbott Nature
Antoine Brill Servier
Pierre De Meyts Novo Nordisk
Gerard Drewes Cellzome
Martin Ebeling Roche
Ron Germain NIAID, NIH
Gabriel Hemlinger Novartis
Adriano Henney AstraZeneca
Anders Karlström AstraZeneca
Douglas Kell University of Manchester
Hiroaki Kitano Systems Biology Institute, Japan/ Sony Research Labs
Edda Klipp Humboldt University
Joanne Kotz Nature Chemical Biology
Joseph Lehar CombinatoRx
Clare McVicker Wellcome Trust
Franzisca Michor Memorial Sloane Kettering Cancer Center
Cristiano Migliorini Roche
Colin Miles BBSRC
Denis Noble University of Oxford
Bernhard Palsson UCSD
Robert Powell FDA
John Quackenbush Dana Farber Cancer Institute
Saroja Ramanujan Entelos Inc
Don Stanski Novartis
Giulio Superti-Furga CeMM, Austrian Academy of Sciences
Antonella Viola Humanitas Institute/ Venetian Institute of Molecular
Medicine/ University of Milan
Johanna Wahlberg AstraZeneca
Hans Westerhoff University of Manchester/ University of Amsterdam